Floatz logo

Siponimod

Secondary Progressive Multiple Sclerosis

Novartis PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

36 Active assets in the Secondary Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fampridine
University College Dublin
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Cairo University
Phase 3BB
bnt162
Novartis Pharmaceuticals
Phase 4BB
mis416
Innate Immunotherapeutics
Phase 2BB
Natalizumab
Biogen
Phase 3BB

View all 50 →

Same molecule, other indications

Siponimod is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
64 / 100
View asset →
hemorrhagic strokeDormant
B
Indicative ·
57 / 100
View asset →
intracerebral hemorrhageDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →